Literature DB >> 17353190

Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations.

Maria F Pino1, Kyoung-Ah Kim, Kathy D Shelton, Jill Lindner, Stella Odili, Changhong Li, Heather W Collins, Masakazu Shiota, Franz M Matschinsky, Mark A Magnuson.   

Abstract

To better understand how glucokinase (GK) missense mutations associated with human glycemic diseases perturb glucose homeostasis, we generated and characterized mice with either an activating (A456V) or inactivating (K414E) mutation in the gk gene. Animals with these mutations exhibited alterations in their blood glucose concentration that were inversely related to the relative activity index of GK. Moreover, the threshold for glucose-stimulated insulin secretion from islets with either the activating or inactivating mutation were left- or right-shifted, respectively. However, we were surprised to find that mice with the activating mutation had markedly reduced amounts of hepatic GK activity. Further studies of bacterially expressed mutant enzymes revealed that GK(A456V) is as stable as the wild type enzyme, whereas GK(K414E) is thermolabile. However, the ability of GK regulatory protein to inhibit GK(A456V) was found to be less than that of the wild type enzyme, a finding consistent with impaired hepatic nuclear localization. Taken together, this study indicates that it is necessary to have knowledge of both thermolability and the interactions of mutant GK enzymes with GK regulatory protein when attempting to predict in vivo glycemic phenotypes based on the measurement of enzyme kinetics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353190     DOI: 10.1074/jbc.M610094200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation.

Authors:  Maria Negahdar; Ingvild Aukrust; Bente B Johansson; Janne Molnes; Anders Molven; Franz M Matschinsky; Oddmund Søvik; Rohit N Kulkarni; Torgeir Flatmark; Pål Rasmus Njølstad; Lise Bjørkhaug
Journal:  Biochim Biophys Acta       Date:  2012-07-20

2.  S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Yves Charton; Solo Goldstein; Françoise Perron-Sierra; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Marjorie Sadlo; Elizabeth Harley; Cédric Vinson; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 3.  Nutrient sensing in pancreatic islets: lessons from congenital hyperinsulinism and monogenic diabetes.

Authors:  Ming Lu; Changhong Li
Journal:  Ann N Y Acad Sci       Date:  2017-10-16       Impact factor: 5.691

4.  Nitric Oxide Activates β-Cell Glucokinase by Promoting Formation of the "Glucose-Activated" State.

Authors:  Kendra M Seckinger; Vishnu P Rao; Nicole E Snell; Allison E Mancini; Michele L Markwardt; M A Rizzo
Journal:  Biochemistry       Date:  2018-08-10       Impact factor: 3.162

5.  The GCKR Gene Polymorphism rs780094 is a Risk Factor for Gestational Diabetes in a Brazilian Population.

Authors:  Mauren Isfer Anghebem-Oliveira; Susan Webber; Dayane Alberton; Emanuel Maltempi de Souza; Giseli Klassen; Geraldo Picheth; Fabiane Gomes de Moraes Rego
Journal:  J Clin Lab Anal       Date:  2016-08-24       Impact factor: 2.352

6.  Heterologous overexpression of active hexokinases from microsporidia Nosema bombycis and Nosema ceranae confirms their ability to phosphorylate host glucose.

Authors:  Viacheslav V Dolgikh; Alexander A Tsarev; Sergey A Timofeev; Vladimir S Zhuravlyov
Journal:  Parasitol Res       Date:  2019-03-13       Impact factor: 2.289

Review 7.  Assessing the potential of glucokinase activators in diabetes therapy.

Authors:  Franz M Matschinsky
Journal:  Nat Rev Drug Discov       Date:  2009-04-17       Impact factor: 84.694

8.  Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Thierry Umbdenstock; Cédric Vinson; Murielle Combettes; Brant de Fanti; Elizabeth Harley; Marjorie Sadlo; Anne-Laure Lefèvre; Olivier Broux; Michel Wierzbicki; Jean-Marie Fourquez; Françoise Perron-Sierra; András Kotschy; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

9.  Generation of N-ethyl-N-nitrosourea (ENU) diabetes models in mice demonstrates genotype-specific action of glucokinase activators.

Authors:  Deborah Fenner; Stella Odili; Hee-Kyung Hong; Yumiko Kobayashi; Akira Kohsaka; Sandra M Siepka; Martha H Vitaterna; Pan Chen; Bogumil Zelent; Joseph Grimsby; Joseph S Takahashi; Franz M Matschinsky; Joseph Bass
Journal:  J Biol Chem       Date:  2011-09-15       Impact factor: 5.157

Review 10.  Molecular physiology of mammalian glucokinase.

Authors:  P B Iynedjian
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.